Axsome v. Aurobindo: Sunosi® Solriamfetol Patent Dispute Consolidated in New Jersey
Axsome Malta Ltd. and Axsome Therapeutics, Inc. brought an Orange Book patent infringement action against Aurobindo Pharma over generic solriamfetol tablets (75 mg and 150 mg). Filed July 2, 2024 and resolved in 84 days, the case was consolidated into a broader multi-defendant ANDA litigation — one of at least eight related actions targeting generic challengers to Sunosi®.
Axsome’s Sunosi® ANDA War Expands to Aurobindo in New Jersey
On July 2, 2024, Axsome Malta Ltd. and Axsome Therapeutics, Inc. filed Civil Action No. 2:24-cv-07511 in the District of New Jersey against Aurobindo Pharma USA, Inc. and Aurobindo Pharma Limited, alleging infringement of Orange Book-listed patents covering Sunosi® (solriamfetol) oral tablets — specifically the 75 mg and 150 mg dosage strengths. The asserted patent, US11969404B2, relates to solriamfetol formulations, a dopamine and norepinephrine reuptake inhibitor approved for excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea.
Within 84 days of filing, on September 24, 2024, the case was terminated by consolidation into the Main Action (No. 23-20354), which by that point encompassed related actions against Alkem Laboratories, Hetero entities, and Hikma Pharmaceuticals. Consolidation does not resolve the underlying infringement claims on the merits; rather, it brings all related ANDA challenges against Sunosi® into a single coordinated proceeding, allowing for unified discovery, claim construction, and trial scheduling.
The 84-day case duration reflects efficient judicial housekeeping rather than any substantive resolution — a pattern consistent with how New Jersey courts manage complex multi-ANDA pharmaceutical litigations. Notably, Axsome filed at least two additional actions against Aurobindo in August and September 2024 (Nos. 24-8365 and 24-8624), all folded into the same consolidation order, suggesting Aurobindo filed successive ANDA amendments or paragraph IV certifications across the same product. The ultimate merits outcome — and any 30-month stay implications — will be determined within the Main Action.
Filing to Case Consolidated in 84 days
84-day lifespan — rapid consolidation into the multi-defendant Main Action
Case consolidated: what the merger into the Main Action means for both parties
Consolidation terminates the docket — not the dispute
Case consolidation under Fed. R. Civ. P. 42(a) merges related actions sharing common questions of law or fact into a single proceeding. Here, the New Jersey court absorbed this Aurobindo action into Main Action No. 23-20354. The infringement claims survive intact; only the separate docket is closed. All future filings, discovery, and rulings will occur under the Main Action case number.
No merits ruling issuedAxsome gains a unified litigation front for Sunosi® defence
Consolidation is strategically advantageous for Axsome: a single proceeding means one claim construction ruling, coordinated discovery against multiple generic filers, and reduced risk of inconsistent judgments. With at least four remaining generic defendants (Alkem, Aurobindo, Hetero, Hikma), Axsome can pursue a coordinated strategy to protect Sunosi®’s market exclusivity through the 30-month stay period triggered by timely patent suit filing.
Consolidated prosecution continuesAurobindo must defend in a multi-party ANDA proceeding
For Aurobindo, consolidation means litigation costs and discovery obligations are shared with other generic defendants, which can reduce individual burden. However, it also means any adverse claim construction ruling will bind all defendants simultaneously. Aurobindo remains subject to the 30-month stay mechanism, which could delay FDA final approval of its solriamfetol ANDA pending resolution of the consolidated merits.
30-month stay implications remainMulti-ANDA consolidation raises the stakes for the entire generic field
The consolidation of at least eight related actions into one proceeding signals that Axsome is mounting a comprehensive Orange Book defence of Sunosi®. Solriamfetol targets a high-value sleep disorder market. A single merits ruling in the Main Action will simultaneously determine all generic challengers’ paths to market, making the consolidated proceeding a high-impact event for the wakefulness-promoting drug sector.
High-stakes coordinated defenceFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Axsome Malta, Ltd. | Company | Pharmaceutical company — holder of US11969404B2 covering Sunosi® (solriamfetol) tabletsSearch in Eureka ↗ |
| Co-Plaintiff | Axsome Therapeutics, Inc. | Company | Search in Eureka ↗ |
| Defendant | Aurobindo Pharma, Ltd. | Company | Generic pharmaceutical manufacturer seeking ANDA approval for solriamfetol oral tabletsSearch in Eureka ↗ |
| Co-Defendant | Aurobindo Pharma Limited, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing Axsome Malta, Ltd.Search in Eureka ↗ |
| Defendant counsel | WILLIAM HARE | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant law firm | McNeely, Hare & War LLP | Law Firm | Representing Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order reflects a procedural merger rather than any adjudication on infringement or patent validity. The court’s language — incorporating multiple related civil actions into the Main Action — confirms that all substantive claims under US11969404B2 remain live. For practitioners, the key analytical question shifts to the Main Action (No. 23-20354): claim construction scheduling, any IPR filings against the asserted patent, and whether any defendant has moved for early summary judgment on non-infringement.
US11969404B2 — Solriamfetol Oral Tablet Formulation (Sunosi®)
US11969404B2 is listed in the FDA Orange Book for Sunosi® (solriamfetol), a selective dopamine and norepinephrine reuptake inhibitor (DNRI) indicated for excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea. Orange Book listing triggers the automatic 30-month stay mechanism under the Hatch-Waxman Act when suit is filed within 45 days of paragraph IV certification notice, making this patent the central gatekeeper for generic solriamfetol market entry. The application number US18/295138 suggests a relatively recent continuation or divisional filing, consistent with lifecycle management strategies used to extend exclusivity on approved drug products.
Solriamfetol was originally developed by Jazz Pharmaceuticals and later acquired by Axsome; its patent estate is the subject of coordinated enforcement across at least eight ANDA filers. For generic manufacturers, US11969404B2 represents a high-priority invalidity and non-infringement analysis target. Any IPR petition filed against this patent at the USPTO would run parallel to the consolidated district court proceeding, creating dual-track risk for Axsome. Competitors not yet named in litigation — and those evaluating solriamfetol pipeline products — should conduct freedom-to-operate analysis against the full Orange Book patent cluster, not just the single asserted patent.
Should you run an FTO analysis against US11969404B2 and the Sunosi® patent cluster?
Any company developing, manufacturing, or commercialising solriamfetol oral solid dosage forms — including 75 mg and 150 mg tablet strengths — should treat US11969404B2 as a priority clearance target. The ongoing consolidated litigation against four generic defendants confirms that Axsome actively enforces this Orange Book listing. R&D teams working on DNRI-class wakefulness agents, sleep disorder treatments, or solriamfetol API sourcing should also assess the broader continuation patent family stemming from application US18/295138.
PatSnap Eureka’s FTO Search Agent can map the full claim scope of US11969404B2 against your product specifications, identify related family members and continuation applications, flag co-pending applications that could issue and expand the claim fence, and surface prior art relevant to invalidity arguments. For ANDA filers already in the Main Action, Eureka can help track IPR filing windows and monitor the consolidated docket for claim construction orders that may affect your paragraph IV certification strategy.
Run a freedom-to-operate analysis on US11969404B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA Solriamfetol and Wakefulness Drug Patent Cases in New Jersey
Related Orange Book patent enforcement actions for Sunosi® (solriamfetol) and comparable ANDA multi-defendant consolidations in the District of New Jersey.
What this case signals for the pharmaceutical ANDA IP landscape
Axsome’s multi-front Orange Book enforcement strategy for Sunosi® illustrates how branded pharma companies use serial ANDA litigation and consolidation to maximise stay periods.
Serial ANDA filings by Aurobindo triggered multiple patent suits
Axsome filed at least three separate actions against Aurobindo entities between July and September 2024, suggesting Aurobindo submitted successive ANDA filings or amended its paragraph IV certifications. Generic filers should expect each new filing to generate a fresh 45-day window for patent suit and a potential new 30-month stay clock.
New Jersey ANDA consolidations move quickly — 84 days to merger
The District of New Jersey, a leading ANDA litigation venue, consolidated this action in under three months. IP teams monitoring Sunosi® competitor activity should track the Main Action (No. 23-20354) directly, as all substantive rulings — claim construction, summary judgment, trial — will issue there, not on individual dockets.
Axsome v Aurobindo — key questions answered
The case was filed on July 2, 2024 by Axsome Malta Ltd. and Axsome Therapeutics, Inc. against Aurobindo Pharma entities in the District of New Jersey, asserting infringement of US11969404B2 covering Sunosi® (solriamfetol) tablets. It was terminated on September 24, 2024 — 84 days after filing — by consolidation into Main Action No. 23-20354, which coordinates all Sunosi® ANDA litigation in New Jersey. No merits ruling was issued in the standalone docket.
US11969404B2 is a patent covering solriamfetol oral tablet formulations and is listed in the FDA Orange Book for Sunosi® (solriamfetol 75 mg and 150 mg tablets). Orange Book listing means any ANDA filer seeking approval for a generic version must address the patent via a paragraph IV certification, which in turn allows Axsome to sue within 45 days and trigger a 30-month stay of FDA final approval. The application number US18/295138 suggests it is a continuation-family patent.
Consolidation under Fed. R. Civ. P. 42(a) merges the separate Aurobindo docket into Main Action No. 23-20354 but does not dismiss or resolve the underlying infringement claims. Axsome’s allegations that Aurobindo’s generic solriamfetol tablets infringe US11969404B2 remain active and will be litigated alongside claims against Alkem, Hetero, and Hikma in the consolidated proceeding.
The Main Action (No. 23-20354) initially named Alkem Laboratories, Aurobindo Pharma USA, Hetero entities, Hikma Pharmaceuticals, Sandoz, and Unichem Laboratories as defendants. By September 2024, Unichem was dismissed (June 2024) and Sandoz was dismissed (September 2024), leaving Alkem, Aurobindo, Hetero, and Hikma as the remaining generic challengers in the consolidated proceeding.
Under the Hatch-Waxman Act, if Axsome filed suit within 45 days of receiving Aurobindo’s paragraph IV certification notice, FDA approval of Aurobindo’s solriamfetol ANDA is automatically stayed for 30 months from the date of the notice letter, or until a court judgment of invalidity or non-infringement — whichever comes first. The public record of this case is consistent with timely filing, but confirmation of the exact notification date and stay expiry would require review of the Main Action docket.
PatSnap Eureka searches patents and litigation data to answer instantly.